"Biodesix delivered exceptional first quarter results that reflect strong momentum across both our Diagnostic Testing and our Development Services business,” said Scott Hutton, Chief Executive Officer ...

Total test volumes grew 29% year over year due to increased adoption from both pulmonology and primary care, with test ...

Q1 2026 earnings call: 42% revenue growth, margin expansion, Nodify Lung adoption and raised 2026 guidance to $108–$114M—read now.

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

GDDY trades at just 10x forward earnings and 8.3x forward EV/EBITDA, with a 2026 free cash flow yield estimate of 15.5%, ...

Ongoing conflict shows that digital disruptions might be sudden, interconnected, and far-reaching. Systems would be tested ...

Revenue amounted to EUR 624.2 million (EUR 578.1 million), an increase of 8.0% with an organic growth of 10.3%.Operating pro?t (EBIT) was EUR 46.7 million (EUR 36.0 million), an increase of 30.0% repr ...

In modern drug discovery, successfully navigating the progress from molecular concept to viable therapeutic often hinges on the quality, accessibility, and interpretability of the data guiding each ...

Building Vigilent.ai, a prototype AI application designed to process adverse event cases in the highly regulated ...

Thomas Reardon is raising $500M at a $2.5B valuation for Flourish, which uses neuroscience to make AI radically less power-hungry. Lux Capital and GV lead the round.

Automated vehicles have been steadily rolling out in U.S. cities, but scaled deployment still faces a daunting challenge: ...